hrp0097p1-486 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Severe hypercalcemia due to subcutaneous fat necrosis despite minimal skin lesions in a newborn: a case report

Berkenbosch Lizanne , Straetemans Saartje

Introduction: Subcutaneous fat necrosis of the newborn (SCFN) is a self-limiting panniculitis which can develop in the first weeks of life. The disorder is characterized by firm, red or purple subcutaneous nodules and plaques on the trunk, buttocks, cheeks, and extremities and is associated with perinatal stress. SCFN may lead to hypoglycemia, anemia, thrombocytopenia, hypertriglyceridemia and hypercalcemia. The proposed mechanism for the hypercalcemia is extr...

hrp0082p2-d2-472 | Growth (1) | ESPE2014

Body Proportions Estimated by Photometry

Gerver Willem Jan , Brecheisen Ralph , Penders Bas , Straetemans Saartje

Background: The growth process that transforms a newborn into an adult implies that there is not only an increase in height but above all a constant change in body proportions. Knowledge of the body proportions gives insight into the natural process of maturation and any disturbance can be used as a diagnostic tool.Objective and hypotheses: Manual measurement of body dimensions is a highly time-consuming procedure requiring a variety of measurement tools...

hrp0086p1-p599 | Growth P1 | ESPE2016

Validation of Prediction Models for Near Final Adult Height in Children with Idiopathic Growth Hormone Deficiency Treated with Growth Hormone for 1 Year

Straetemans Saartje , De Schepper Jean , Thomas Muriel , Verlinde Franciska , Rooman Raoul

Background: An accurate prediction of final height after the first year of growth hormone (GH) treatment may help clinicians to give parents and children more realistic expectations.Objective and hypotheses: To validate two prediction models (with and without max. GH peak) for near final adult height (nFAH) by Ranke et al.Method: Height data of 142 (93 male) idiopathic GH deficient (iGHD) children, treated with GH for at l...

hrp0082p2-d3-435 | Growth Hormone (2) | ESPE2014

First-year Growth Response to GH in Relation to Final Height Outcome in Prepubertal Children with Idiopathic GH Deficiency

Straetemans Saartje , Thomas Muriel , Tenoutasse Sylvie , De Schepper Jean , Rooman Raoul

Background: Several definitions of poor growth response to first-year GH treatment, have been proposed based on the observed response of a large group of patients.Objective and hypotheses: Since a complete compensation of the height deficit is expected in children with GH deficiency (GHD) treated with GH, we have studied the different parameters for the first-year growth response in relation to the adult height gain in prepubertal children with iGHD....

hrp0084p2-300 | Diabetes | ESPE2015

Non-Immune Diabetes Mellitus and Neurodegeneration: Two Distinct Cases of Wolfram Syndrome

Lemay Annelies , Sinnema Margje , den Brinker Marieke , Dotremont Hilde , France Annick , Rooman Raoul , Straetemans Saartje

Background: Wolfram syndrome features diabetes insipidus, diabetes mellitus, optic nerve atrophy, and deafness (DIDMOAD). Especially the neurological degeneration usually leads to a very poor prognosis. We present two cases of Wolfram syndrome, an autosomal dominant and an autosomal recessive type, caused by heterozygous mutations in the WFS1 gene.Case report: Case 1: a 13-year-old girl with a history of progressive sensorineuronal hearing loss ...

hrp0092p2-153 | GH and IGFs | ESPE2019

Criteria for First-Year Growth Response to Growth Hormone Treatment in Prepubertal Children with Growth Hormone Deficiency: Do they Predict Final Height Outcome?

Straetemans Saartje , De Schepper Jean , Thomas Muriel , Tenoutasse Sylvie , Beauloye Véronique , Rooman Raoul , BESPEED the members of

Background/Aim: Several criteria for the first year growth response (FYGR) to growth hormone (GH) treatment have been proposed. We explored which FYGR criteria predict best the final height outcome after GH treatment in prepubertal children with GH deficiency (GHD).Methods: Height data of 129 GHD children (83 boys) treated with GH for at least 4 consecutive years with at least 1 year before pubertal onset, were retrieved...

hrp0084p2-197 | Adrenals | ESPE2015

Evaluation of Medical Treatment in the First 2 Years of Life with a New Dutch National Longitudinal Registry for Children with Congenital Adrenal Hyperplasia (CAH)

van der Linde Annelieke , van den Akker Erica , Bakker- van Waarde Willy , Hannema Sabine , Hoorweg-Nijman Gea , van de Kamp Hetty , Klink Daniel , Odink Roelof , Straetemans Saartje , van Trotsenburg Paul , Verkerk Paul , Claahsen-van der Grinten Hedi

Background: Recently, a national database has been developed to register yearly data from all children detected with CAH in the neonatal screening program from 2002 onwards. So far longitudinal data of 105 children have been registered (roughly 65% of Dutch CAH patients) to evaluate medical treatment and long-term effects in CAH. A national CAH work group developed guidelines for diagnostics and follow up in CAH.Objective and hypotheses: Aim of our curre...

hrp0094p1-1 | Adrenal A | ESPE2021

Optimizing the timing of highest hydrocortisone dose in children and adolescents with 21-hydroxylase deficiency

Schroder Mariska A.M. , van Herwaarden Antonius E. , Span Paul N. , Akker Erica L.T. van den , Bocca Gianni , Hannema Sabine E , Kamp Hetty J. van der , Kort Sandra W.K. de , Mooij Christiaan F. , Schott Dina A. , Straetemans Saartje , Tellingen Vera van , Velden Janielle A. van der , Sweep Fred C.G.J , Claahsen-van der Grinten Hedi L. ,

Context: Children with 21-hydroxylase deficiency (21OHD) require chronic glucocorticoid administration to substitute glucocorticoids and suppress adrenocorticotropic hormone-induced hyperandrogenemia. There is still no evidence about the best timing of the highest hydrocortisone (HC) dose. Administration of the highest dose in the morning aims to mimic the physiological rhythm of cortisol, while a high dose late in the evening may inhibit the early-morning inc...